Diabetic Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.
The Diabetic Macular Edema drugs in development market research report provide comprehensive information on the therapeutics under development for Diabetic Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects.
Key Targets in the Diabetic Macular Edema Pipeline Products Market
The key targets in the Diabetic Macular Edema pipeline products market are Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Placenta Growth Factor, Plasma Kallikrein, Glucocorticoid Receptor, Angiopoietin 1 Receptor, Angiopoietin 2, Semaphorin 3A, Vascular Endothelial Growth Factor Receptor, Apoptosis Regulator Bcl 2, and others.
Diabetic Macular Edema Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Diabetic Macular Edema Pipeline Products Market
The key mechanisms of action in the Diabetic Macular Edema pipeline products market are Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Placenta Growth Factor Inhibitor, Plasma Kallikrein Inhibitor, Glucocorticoid Receptor Agonist, Angiopoietin 2 Inhibitor, Semaphorin 3A Inhibitor, Angiopoietin 1 Receptor Agonist, Apoptosis Regulator Bcl 2 Inhibitor, DNA (Apurinic or Apyrimidinic Site) Lyase Inhibitor, and others.
Diabetic Macular Edema Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Diabetic Macular Edema Pipeline Products Market
The key routes of administration in the Diabetic Macular Edema pipeline products market are intravitreal, oral, ophthalmic, intraocular, parenteral, topical, intravenous, subcutaneous, buccal, conjunctival, and others.
Diabetic Macular Edema Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Diabetic Macular Edema Pipeline Products Market
The key molecule types in the Diabetic Macular Edema pipeline products market are small molecule, monoclonal antibody, fusion protein, synthetic peptide, gene therapy, recombinant protein, protein, antisense oligonucleotide, aptamer, cell therapy, and others.
Diabetic Macular Edema Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Diabetic Macular Edema Pipeline Products Market
Some of the major companies in the Diabetic Macular Edema pipeline products market are F. Hoffmann-La Roche Ltd, ANBITION Srl, Ocular Therapeutix Inc, Ascentage Pharma Group International, Avirmax Inc, Clearside BioMedical Inc, Kalvista Pharmaceuticals Inc, Samsung Bioepis Co Ltd, Aadi Bioscience Inc, and Aerie Pharmaceuticals Inc.
Diabetic Macular Edema Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
Key targets | Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Placenta Growth Factor, Plasma Kallikrein, Glucocorticoid Receptor, Angiopoietin 1 Receptor, Angiopoietin 2, Semaphorin 3A, Vascular Endothelial Growth Factor Receptor, Apoptosis Regulator Bcl 2, and Others |
Key mechanism of action | Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Placenta Growth Factor Inhibitor, Plasma Kallikrein Inhibitor, Glucocorticoid Receptor Agonist, Angiopoietin 2 Inhibitor, Semaphorin 3A Inhibitor, Angiopoietin 1 Receptor Agonist, Apoptosis Regulator Bcl 2 Inhibitor, DNA (Apurinic or Apyrimidinic Site) Lyase Inhibitor, and Others |
Key routes of administration | Intravitreal, Oral, Ophthalmic, Intraocular, Parenteral, Topical, Intravenous, Subcutaneous, Buccal, Conjunctival, and Others |
Key molecule type | Small Molecule, Monoclonal Antibody, Fusion Protein, Synthetic Peptide, Gene Therapy, Recombinant Protein, Protein, Antisense Oligonucleotide, Aptamer, Cell Therapy, and Others |
Major companies | F. Hoffmann-La Roche Ltd, ANBITION Srl, Ocular Therapeutix Inc, Ascentage Pharma Group International, Avirmax Inc, Clearside BioMedical Inc, Kalvista Pharmaceuticals Inc, Samsung Bioepis Co Ltd, Aadi Bioscience Inc, and Aerie Pharmaceuticals Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
4D Molecular Therapeutics Inc
Aadi Bioscience Inc
Abpro Corp
Aciont Inc
Aerie Pharmaceuticals Inc
Aldeyra Therapeutics Inc
Allegro Ophthalmics LLC
Allgenesis Biotherapeutics Inc
AmMax Bio Inc
Ampio Pharmaceuticals Inc
ANBITION Srl
Apexian Pharmaceuticals Inc
Araim Pharmaceuticals Inc
Ascentage Pharma Group International
AsclepiX Therapeutics Inc
Ashvattha Therapeutics LLC
AskGene Pharma Inc
Avirmax Inc
BetaStem Therapeutics Inc
Bio-Thera Solutions Ltd
BioCryst Pharmaceuticals Inc
Cell Care Therapeutics Inc
Celltrion Inc
Celon Pharma SA
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chiome Bioscience Inc
Clearside BioMedical Inc
Curacle Co Ltd
Drive Therapeutics LLC
Elasmogen Ltd
Eluminex Biosciences Ltd
Everglades Biopharma LLC
Exonate Ltd
EyeGene Inc
F. Hoffmann-La Roche Ltd
Gene Signal International SA
GlaxoSmithKline Plc
Graybug Vision Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Huabo Biopharm (Shanghai) Co Ltd
Huadong Medicine Co Ltd
Ikarovec Ltd
Innovent Biologics Inc
Isarna Therapeutics GmbH
Johnson & Johnson
Kala Pharmaceuticals Inc
Kalos Therapeutics Inc
Kalvista Pharmaceuticals Inc
Kanaph Therapeutics Inc
Kiora Pharmaceuticals Inc
Kodiak Sciences Inc
Kowa Co Ltd
Kubota Vision Inc
Kuur Therapeutics Ltd
Laboratorios Sophia SA de CV
Luye Pharma Group Ltd
Mabion SA
Mabwell Shanghai Bioscience Co Ltd
Molecular Partners AG
NeuMedics Inc
Novartis AG
Novelty Nobility Inc
Noveome Biotherapeutics Inc
Oak Hill Bio Inc
OccuRx Pty Ltd
Ocugen Inc
Ocular Therapeutix Inc
Oculis SA
OcuNexus Therapeutics Inc
OcuTerra Therapeutics Inc
Opthea Ltd
Outlook Therapeutics Inc
Oxular Ltd
Oxurion NV
PanOptica Inc
Phanes Therapeutics Inc
PharmAbcine Inc
Pleryon Therapeutics Ltd
Profarma
Qilu Pharmaceutical Co Ltd
Rebio Technologies Ltd
Regeneron Pharmaceuticals Inc
RemeGen Co Ltd
Rezolute Inc
RiniSight Inc
Ripple therapeutics Corp
Samsung Bioepis Co Ltd
Semathera Inc
Senju Pharmaceutical Co Ltd
Shanghai SIMR Biotech Co Ltd
Surrozen Inc
Suzhou Stainwei Biotech Inc
Targeted Therapy Technologies LLC
Theravance Biopharma Inc
Uni-Bio Science Group Ltd
Unity Biotechnology Inc
Verseon Corp
Xbrane Biopharma AB
YD Life Science Co
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Diabetic Macular Edema pipeline products market?
The key targets in the Diabetic Macular Edema pipeline products market are Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor, Placenta Growth Factor, Plasma Kallikrein, Glucocorticoid Receptor, Angiopoietin 1 Receptor, Angiopoietin 2, Semaphorin 3A, Vascular Endothelial Growth Factor Receptor, Apoptosis Regulator Bcl 2, and others.
-
What are the key mechanisms of action in the Diabetic Macular Edema pipeline products market?
The key mechanisms of action in the Diabetic Macular Edema pipeline products market are Vascular Endothelial Growth Factor A Inhibitor, Vascular Endothelial Growth Factor Inhibitor, Placenta Growth Factor Inhibitor, Plasma Kallikrein Inhibitor, Glucocorticoid Receptor Agonist, Angiopoietin 2 Inhibitor, Semaphorin 3A Inhibitor, Angiopoietin 1 Receptor Agonist, Apoptosis Regulator Bcl 2 Inhibitor, DNA (Apurinic or Apyrimidinic Site) Lyase Inhibitor, and others.
-
What are the key routes of administration in the Diabetic Macular Edema pipeline products market?
The key routes of administration in the Diabetic Macular Edema pipeline products market are intravitreal, oral, ophthalmic, intraocular, parenteral, topical, intravenous, subcutaneous, buccal, conjunctival, and others.
-
What are the key molecule types in the Diabetic Macular Edema pipeline products market?
The key molecule types in the Diabetic Macular Edema pipeline products market are small molecule, monoclonal antibody, fusion protein, synthetic peptide, gene therapy, recombinant protein, protein, antisense oligonucleotide, aptamer, cell therapy, and others.
-
Which are the major companies in the Diabetic Macular Edema pipeline products market?
Some of the major companies in the Diabetic Macular Edema pipeline products market are F. Hoffmann-La Roche Ltd, ANBITION Srl, Ocular Therapeutix Inc, Ascentage Pharma Group International, Avirmax Inc, Clearside BioMedical Inc, Kalvista Pharmaceuticals Inc, Samsung Bioepis Co Ltd, Aadi Bioscience Inc, and Aerie Pharmaceuticals Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.